In contrast, monogenic BRCA2 or RAD51C tumor mutations confer only a minor but insignificant decrease in overall survival compared to patients with no BRCA2 or RAD51C mutation (Fig. 5a), revealing genetic vulnerability associated with the polygenic BRCA2 + RAD51C mutations. This evidence concerns the gene BRCA2 and neoplasm.